Eptifibatide is an antiplatelet agent used to prevent blood clot formation, significantly reducing the risk of myocardial infarction (heart attack). It is primarily indicated for the treatment of acute coronary syndrome (ACS) in patients requiring medical management or percutaneous coronary intervention (PCI). ACS encompasses serious cardiac conditions where blood flow to the heart is compromised due to plaque buildup. Eptifibatide is also beneficial for patients undergoing urgent PCI procedures and intracoronary stenting. By inhibiting glycoprotein IIb/IIIa receptors on platelets, Eptifibatide prevents platelet aggregation and fibrinogen binding, thus lowering the risk of cardiovascular events. In summary, Eptifibatide effectively reduces the risk of heart-related complications by preventing blood clots.
Eptifibatide works by reversibly binding to the glycoprotein IIb/IIIa receptors on platelets, inhibiting their aggregation and preventing thrombus formation.
No published brands for this salt yet.